AI’s Increasing Capacity to Outperform Human Detection of Lung Cancer
AI detects lung cancer better than humans do.
AI detects lung cancer better than humans do.
Ultrasensitive Circulating Tumor DNA improves clinical sensitivity of minimal residual disease in early stage non-small cell lung cancer.
The treatment landscape for non-small cell lung cancer has significantly evolved with the advent of targeted therapies.
The following is a summary of “J-TAIL-2: A prospective observational study of atezolizumab...
The following is a summary of “Assessing quality of care in early-stage resected stage...
The following is a summary of “Young adults (YA) with non-small cell lung cancer (NSCLC):...
ASCO Voices has become an anticipated staple of the conference. It is an opportunity for physicians to share their platform and experiences on a scale unlike any other.
Are you traveling to Chicago for ASCO? Here's some places to visit.
What ASCO ancillary event are you excited to attend?
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.